Navigation

Lung cancer (non small cell, non squamous) - pemetrexed (maintenance following pemetrexed & cisplatin) [ID489]

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer

Status: In development
Expected date of issue: April 2014
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21

Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Mark Minchin
Communications manager: Alice Law
Project manager:

Kate Moore

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 15 October 2012
1st appraisal committee meeting: 29 January 2013
2nd appraisal committee meeting 30 April 2013
3rd appraisal committee meeting: 25 September 2013
4th appraisal committee meeting: 14 January 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Lilly UK (pemetrexed)

Patient/carer groups

  • Roy Castle Lung Cancer Foundation

Professional groups

  • British Thoracic Society
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS England
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

  • British Thoracic Oncology Group

Evidence Review Group

  • Liverpool Reviews and Implementation Group (LRIG)
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • None

Top


 

Project history

Date Update
12 November 2013 Following the committee meeting on 25 September 2013 On 7 October 2013, The Institute was asked to prepare an Appraisal Consultation Document (ACD). As a consequence of having to confirm the confidentiality status of some of the information used in the appraisal, the release of the Appraisal Consultation Document has been delayed.
20 August 2013 Following the release of the Final Appraisal Determination (FAD) in June 2013 and receipt of an appeal lodged by Eli Lilly and company, NICE has realised that a procedural error has been made in the handling of the technology appraisal of pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous NSCLC. The Appraisal Consultation Document (ACD) below has therefore been released for public consultation and a document that describes the technical detail of the exploratory analyses by the evidence review group is made available as part of the evaluation report accompanying the ACD.
2 August 2013 On receipt of an appeal lodged by Eli Lilly and company we have realised that a procedural error has been made in the handling of the technology appraisal of pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous NSCLC.
As a consequence, we will be retracting the Final Appraisal Determination (FAD) as issued on the 6 June 2013, and instead we will be releasing an Appraisal Consultation Document (ACD) for public consultation.
A document that describes the technical detail of the exploratory analyses by the evidence review group will be made available to consultees and commentators as part of the evaluation report accompanying the ACD. The consultation will not be restricted to only what is in this report.
The Appraisal Committee will consider the responses to the consultation on the ACD at a meeting on Wednesday 25 September 2013.
5 March 2013 NICE released the Appraisal Consultation Document (ACD) for the above appraisal on 14 February 2013. We were made aware that some consultees and commentators did not receive this document. In light of this, we are reissuing the Appraisal Consultation Document (ACD) to all consultees and commentators for a 20 working day consultation. Subsequently, the second committee meeting discussion for pemetrexed, which was originally scheduled for 27 March 2013, has now been rearranged to 30 April 2013.
Top


 

Key documents

This page was last updated: 25 February 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.